Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
ORGANIZATION
Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
It would be difficult to introduce a uniform pricing rule for medically essential but unprofitable drugs in the FY2016 NHI pricing reform to bail out all such products, Shuji Shirakawa, a key member of the Central Social Insurance Medical Council…
To read the full story
Related Article
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Gist of FY2014 NHI Price Revision
December 26, 2013
ORGANIZATION
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…